eligibility_summary
Adults (≥18) with IMWG-defined, measurable multiple myeloma, eligible for commercial tec after ≥4 prior lines (PI, IMiD, CD38 mAb) and refractory/intolerant to other options, ECOG 0–2, >3‑mo survival, eGFR ≥40, AST/ALT ≤3×ULN, bilirubin ≤2×ULN, platelets ≥25k, Hgb ≥7, ANC ≥1000, contraception/consent. Exclude: BCMA therapy <12 mo, active other cancers, ≥10 mg steroids/immunosuppression, recent MM therapy (<7 d), CNS MM, active HBV/HCV/HIV, pregnancy/breastfeeding, QTc ≥500 ms, uncontrolled illness.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1b (terminated for funding) evaluates ST-067 (vevoctadekin) plus teclistamab in relapsed/refractory multiple myeloma. ST-067 is a biological cytokine therapy: a decoy-resistant interleukin-18 (IL-18) variant designed to evade IL-18 binding protein and amplify IL-18 receptor signaling on T and NK cells, enhancing IFN-gamma–driven cytotoxic activity. Teclistamab is a bispecific T-cell–engaging antibody (drug) that binds BCMA on myeloma plasma cells and CD3 on T cells, redirecting T cells to kill BCMA+ tumor cells. Targets/pathways: BCMA+ malignant plasma cells, CD3/TCR signaling on T cells, IL-18/IL-18R pathway on T and NK cells with downstream Th1/IFN-gamma responses.